Becker's Healthcare October 28, 2024
Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and Brigham and Women’s Hospital.
The findings offer a clearer picture of how the growing popularity of GLP-1 weight loss drugs is affecting demand for bariatric surgeries, which have long been the gold standard treatments for weight loss.
“Our study provides one of the first national estimates of the decline in utilization of bariatric metabolic surgery among privately insured patients corresponding to the rising use of blockbuster GLP-1 RA drugs,” Thomas Tsai, MD, senior study author and a metabolic bariatric surgeon at Boston-based Brigham and Women’s Hospital, said in a...
Today's Sponsors
Today's Sponsor